HONG KONG, Dec. 16, 2013 /PRNewswire-FirstCall/ -- China
Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced the
results of its 2013 Annual General Meeting, which was held on
December 16, 2013, in Hong Kong.
At the Annual General Meeting, shareholders
- ratified the appointment of KPMG as the independent auditors of
the Company for the financial year ending March 31, 2014 and authorized any duly formed
committee of the directors to fix the remuneration of the
auditors;
- re-elected Mr. Albert Chen and
Mr. Mark Chen to serve as Class A
Directors of the Company until the 2016 annual general meeting of
members of the Company or until their respective successors are
duly appointed and qualified.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses.
Under current PRC government regulations, only one licensed
cord blood banking operator is permitted to operate in each
licensed region and only seven licenses have been authorized as of
today. China Cord Blood Corporation provides cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services. For more information, please
visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the U.S.
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. Bill Zima
Tel: (+86) 10-6583-7511 (China) or
(+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com
SOURCE China Cord Blood Corporation